AMRX - Amneal Pharmaceuticals to acquire substantially all assets of Kashiv Specialty

Amneal Pharmaceuticals (AMRX) announced that Amneal Pharmaceuticals LLC, a wholly-owned subsidiary of the company will be acquiring a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv BioSciences.Kashiv Specialty Pharmaceuticals is focused on the development of complex generics, innovative drug delivery platforms and novel 505(b) drugs.Under the terms of the transaction, Amneal will pay an upfront purchase price comprised of (i) a cash payment of $70M  and (ii) a cash payment of $30M at the one-year anniversary of the execution of the purchase agreement. Further, Kashiv is also eligible to receive up to an additional $8M in contingent payments upon the achievement of certain regulatory milestones and pay certain royalty payments equal to an escalating percentage of aggregate annual net sales for certain pharmaceutical products.The deal will be financed with cash on hand and is scheduled to complete in the 2Q of 2021."We expect the transaction will be financially

For further details see:

Amneal Pharmaceuticals to acquire substantially all assets of Kashiv Specialty